PKM and colorectal carcinoma: In addition, with gefitinib treatment, the tumors grew at a higher rate in the group showing nuclear PKM2 overexpression than in group used as controls, which suggested that nuclear PKM2 augmented CRC resistance to gefitinib treatment.